SAN DIEGO — More than 40 years ago, Ivor Royston, a brash young assistant professor at University of California, San Diego, made an odd pitch to scientists and pharmaceutical executives across the country: Ditch your jobs and join a fledgling firm working on a new, unproven way to use antibodies to diagnose and even treat deadly diseases.
Turns out it wasn’t an easy sell.
